The First Affiliated Hospital of Xiamen University
Patients with advanced NSCLC underwent 18F-FDG PET/CT and PET/CT-guided synchronous targeted biopsy of primary and distant metastatic tumors. The LIFEx package was used to extract PET and CT radiomic features from primary and metastatic lesions. The radiomic ROI sites of primary and distant metastatic tumors were point-to-point corresponding to the PET/ CT-guided targeted biopsy sites. Whole exon sequencing of primary and distant metastatic tumor samples obtained by PET/CT-guided targeted biopsy was used to get genomic data of primary and distant metastatic tumor. Predictive radiogenomics models were established and validation.
Age
18–90
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
(i) adult patients (aged 18 years or order);
(ii) patients with suspected or newly diagnosed or previously treated malignant tumors (supporting evidence may include magnetic resonance imaging (MRI), CT, tumor markers and pathology report);
(iii) patients who had scheduled both 18F-FDG PET/CT scans and PET/CT guided biopsy;
(iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.
You may not be if
(i) patients with non-malignant lesions;
(ii) patients with pregnancy;
(iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.
